Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 19/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 12/20 | 0.43 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21712385 | 1.00 | TLR7 (0.45) | TLR7TLR8NUDT1 | |
| SCHEMBL25959643 | 1.00 | TLR7 (0.45) | TLR7TLR8NUDT1 | |
| SCHEMBL21730950 | 0.83 | TLR7 (0.46) | TLR7TLR8NUDT1 | |
| SCHEMBL25959653 | 0.82 | TLR7 (0.47) | TLR7TLR8NUDT1 | |
| SCHEMBL21730990 | 0.80 | TLR7 (0.52) | TLR7TLR8NUDT1 | |
| SCHEMBL21730959 | 0.80 | TLR7 (0.52) | TLR7TLR8NUDT1 | |
| SCHEMBL21730949 | 0.80 | TLR7 (0.52) | TLR7TLR8NUDT1 | |
| SCHEMBL21712383 | 0.80 | TLR7 (0.45) | TLR7TLR8NUDT1 | |
| SCHEMBL21712293 | 0.80 | TLR7 (0.45) | TLR7TLR8NUDT1 | |
| SCHEMBL25959636 | 0.80 | TLR7 (0.45) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3615539-B1 | 2-AMINO-QUINOLINE DERIVATIVES | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2023-08-09 | — | — | EP | claimed |
| US-11053240-B2 | 2-amino-quinoline derivatives | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2021-07-06 | — | — | US | claimed |
| US-20200055851-A1 | 2-AMINO-QUINOLINE DERIVATIVES | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2020-02-20 | — | — | US | claimed |
| US-11834448-B2 | 2-amino-quinoline derivatives | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-12-05 | — | — | US | disclosed |
| US-11834448-B2 | 2-amino-quinoline derivatives | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-12-05 | — | — | US | disclosed |
| US-11834448-B2 | 2-amino-quinoline derivatives | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-12-05 | — | — | US | disclosed |
| EP-3615539-B1 | 2-AMINO-QUINOLINE DERIVATIVES | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2023-08-09 | — | — | EP | disclosed |
| EP-3615539-B1 | 2-AMINO-QUINOLINE DERIVATIVES | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2023-08-09 | — | — | EP | disclosed |
| US-11053240-B2 | 2-amino-quinoline derivatives | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2021-07-06 | — | — | US | disclosed |
| US-11053240-B2 | 2-amino-quinoline derivatives | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2021-07-06 | — | — | US | disclosed |
| US-20200055851-A1 | 2-AMINO-QUINOLINE DERIVATIVES | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2020-02-20 | — | — | US | disclosed |
| US-20200055851-A1 | 2-AMINO-QUINOLINE DERIVATIVES | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053240-B2 | 2-amino-quinoline derivatives | TLR7, TLR8, TLR1 | TLR7 1/4885TLR8 2/4885NUDT1 627/4885 |
| US-20200055851-A1 | 2-AMINO-QUINOLINE DERIVATIVES | TLR7, TLR8, TLR1 | TLR7 1/4885TLR8 2/4885NUDT1 627/4885 |
| US-11834448-B2 | 2-amino-quinoline derivatives | TLR7, TLR8, TLR1 | TLR7 1/4885TLR8 2/4885NUDT1 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.